OnCo

Stay in the loop

Leave your email and OnCo will write when something big changes in cancer research. No spam, one click to unsubscribe.

Email updates open shortly. Until then, press Watch on any page to keep it on your list.

trialsTrialActive

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back Af

A phase 3 trial of Fianlimab, Cemiplimab, Pembrolizumab in melanoma, run by Regeneron Pharmaceuticals, active and no longer recruiting.